Carly Luke, Katherine A Benfer, Leeann Mick-Ramsamy, Robert S Ware, Margot Bosanquet, Natasha Reid, Arend F Bos, Roslyn N Boyd
{"title":"预测澳大利亚第一民族婴儿的神经发育结果:早期筛查工具的跨诊断效用。","authors":"Carly Luke, Katherine A Benfer, Leeann Mick-Ramsamy, Robert S Ware, Margot Bosanquet, Natasha Reid, Arend F Bos, Roslyn N Boyd","doi":"10.1111/dmcn.70003","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To determine the predictive relationship between evidence-based screening tools and neurodevelopmental outcomes in Australian First Nations infants.</p><p><strong>Method: </strong>This prospective cohort study invited First Nations families to participate in a culturally adapted early developmental screening programme. A total of 156 infants (55.1% male, mean gestational age = 33.6 weeks, SD = 4.6) were screened using the Prechtl's General Movements Assessment, with optimality scoring using the Motor Optimality Score-Revised (MOS-R) at 3 to 5 months and the Hammersmith Infant Neurological Examination (HINE) at 4 to 9 months. Participants completed 'baby movement (BM) checks' at two time points (BM1, 3-5 months corrected age; BM2, 4-9 months corrected age), with final movement and learning checks at 12 months corrected age. At 12 months corrected age, standardized motor, cognitive, and communication assessments, neurodisability-specific symptomology, or a diagnosis made by a paediatrician classified infants as developing typically ('on track') or (1) with a high chance of or confirmed cerebral palsy (CP) or (2) non-CP neurodevelopmental delay (NDD), including autism and fetal alcohol spectrum disorder (FASD). Predictive relationships were investigated using logistic regression and diagnostic statistics.</p><p><strong>Results: </strong>At 12 months, 127 of 147 (86%) eligible infants (n = 9 withdrawn or deceased) were classified as 'on track' (n = 55, 43%), NDD (n = 59, 47%), or CP (n = 13, 10%). MOS-R (≥ 14 weeks). The HINE distinguished infants as 'on track', CP, or NDD. Each 1-point decrease on both tools increased the odds of NDD (OR<sub>MOS-R</sub> = 1.40, 95% confidence interval [CI] = 1.00-1.96; OR<sub>HINE</sub> = 1.12, 95% CI = 1.05-1.21) and CP (OR<sub>MOS-R</sub> = 1.47, 95% CI = 1.08-2.01; OR<sub>HINE</sub> = 1.41, 95% CI = 1.21-1.65,). The MOS-R (cut-off of less than 23) and HINE (moderate to severely reduced) were best for identifying any NDD and CP (MOS-R: sensitivity = 84%, specificity = 38%; HINE: sensitivity = 64%, specificity = 63%). Combined trajectories across both tools were the strongest predictors of CP (sensitivity = 73%, specificity = 96%), autism (sensitivity = 59%, specificity = 95%), and FASD (sensitivity = 89%, specificity = 93%).</p><p><strong>Interpretation: </strong>Evidence-based screening tools demonstrate promising transdiagnostic prediction of 'on-track' development and not only high chance of CP but also autism, FASD, and other NDDs.</p>","PeriodicalId":50587,"journal":{"name":"Developmental Medicine and Child Neurology","volume":" ","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Predicting neurodevelopmental outcomes in Australian First Nations infants: The transdiagnostic utility of early screening tools.\",\"authors\":\"Carly Luke, Katherine A Benfer, Leeann Mick-Ramsamy, Robert S Ware, Margot Bosanquet, Natasha Reid, Arend F Bos, Roslyn N Boyd\",\"doi\":\"10.1111/dmcn.70003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To determine the predictive relationship between evidence-based screening tools and neurodevelopmental outcomes in Australian First Nations infants.</p><p><strong>Method: </strong>This prospective cohort study invited First Nations families to participate in a culturally adapted early developmental screening programme. A total of 156 infants (55.1% male, mean gestational age = 33.6 weeks, SD = 4.6) were screened using the Prechtl's General Movements Assessment, with optimality scoring using the Motor Optimality Score-Revised (MOS-R) at 3 to 5 months and the Hammersmith Infant Neurological Examination (HINE) at 4 to 9 months. Participants completed 'baby movement (BM) checks' at two time points (BM1, 3-5 months corrected age; BM2, 4-9 months corrected age), with final movement and learning checks at 12 months corrected age. At 12 months corrected age, standardized motor, cognitive, and communication assessments, neurodisability-specific symptomology, or a diagnosis made by a paediatrician classified infants as developing typically ('on track') or (1) with a high chance of or confirmed cerebral palsy (CP) or (2) non-CP neurodevelopmental delay (NDD), including autism and fetal alcohol spectrum disorder (FASD). Predictive relationships were investigated using logistic regression and diagnostic statistics.</p><p><strong>Results: </strong>At 12 months, 127 of 147 (86%) eligible infants (n = 9 withdrawn or deceased) were classified as 'on track' (n = 55, 43%), NDD (n = 59, 47%), or CP (n = 13, 10%). MOS-R (≥ 14 weeks). The HINE distinguished infants as 'on track', CP, or NDD. Each 1-point decrease on both tools increased the odds of NDD (OR<sub>MOS-R</sub> = 1.40, 95% confidence interval [CI] = 1.00-1.96; OR<sub>HINE</sub> = 1.12, 95% CI = 1.05-1.21) and CP (OR<sub>MOS-R</sub> = 1.47, 95% CI = 1.08-2.01; OR<sub>HINE</sub> = 1.41, 95% CI = 1.21-1.65,). The MOS-R (cut-off of less than 23) and HINE (moderate to severely reduced) were best for identifying any NDD and CP (MOS-R: sensitivity = 84%, specificity = 38%; HINE: sensitivity = 64%, specificity = 63%). Combined trajectories across both tools were the strongest predictors of CP (sensitivity = 73%, specificity = 96%), autism (sensitivity = 59%, specificity = 95%), and FASD (sensitivity = 89%, specificity = 93%).</p><p><strong>Interpretation: </strong>Evidence-based screening tools demonstrate promising transdiagnostic prediction of 'on-track' development and not only high chance of CP but also autism, FASD, and other NDDs.</p>\",\"PeriodicalId\":50587,\"journal\":{\"name\":\"Developmental Medicine and Child Neurology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Developmental Medicine and Child Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/dmcn.70003\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Developmental Medicine and Child Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dmcn.70003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Predicting neurodevelopmental outcomes in Australian First Nations infants: The transdiagnostic utility of early screening tools.
Aim: To determine the predictive relationship between evidence-based screening tools and neurodevelopmental outcomes in Australian First Nations infants.
Method: This prospective cohort study invited First Nations families to participate in a culturally adapted early developmental screening programme. A total of 156 infants (55.1% male, mean gestational age = 33.6 weeks, SD = 4.6) were screened using the Prechtl's General Movements Assessment, with optimality scoring using the Motor Optimality Score-Revised (MOS-R) at 3 to 5 months and the Hammersmith Infant Neurological Examination (HINE) at 4 to 9 months. Participants completed 'baby movement (BM) checks' at two time points (BM1, 3-5 months corrected age; BM2, 4-9 months corrected age), with final movement and learning checks at 12 months corrected age. At 12 months corrected age, standardized motor, cognitive, and communication assessments, neurodisability-specific symptomology, or a diagnosis made by a paediatrician classified infants as developing typically ('on track') or (1) with a high chance of or confirmed cerebral palsy (CP) or (2) non-CP neurodevelopmental delay (NDD), including autism and fetal alcohol spectrum disorder (FASD). Predictive relationships were investigated using logistic regression and diagnostic statistics.
Results: At 12 months, 127 of 147 (86%) eligible infants (n = 9 withdrawn or deceased) were classified as 'on track' (n = 55, 43%), NDD (n = 59, 47%), or CP (n = 13, 10%). MOS-R (≥ 14 weeks). The HINE distinguished infants as 'on track', CP, or NDD. Each 1-point decrease on both tools increased the odds of NDD (ORMOS-R = 1.40, 95% confidence interval [CI] = 1.00-1.96; ORHINE = 1.12, 95% CI = 1.05-1.21) and CP (ORMOS-R = 1.47, 95% CI = 1.08-2.01; ORHINE = 1.41, 95% CI = 1.21-1.65,). The MOS-R (cut-off of less than 23) and HINE (moderate to severely reduced) were best for identifying any NDD and CP (MOS-R: sensitivity = 84%, specificity = 38%; HINE: sensitivity = 64%, specificity = 63%). Combined trajectories across both tools were the strongest predictors of CP (sensitivity = 73%, specificity = 96%), autism (sensitivity = 59%, specificity = 95%), and FASD (sensitivity = 89%, specificity = 93%).
Interpretation: Evidence-based screening tools demonstrate promising transdiagnostic prediction of 'on-track' development and not only high chance of CP but also autism, FASD, and other NDDs.
期刊介绍:
Wiley-Blackwell is pleased to publish Developmental Medicine & Child Neurology (DMCN), a Mac Keith Press publication and official journal of the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) and the British Paediatric Neurology Association (BPNA).
For over 50 years, DMCN has defined the field of paediatric neurology and neurodisability and is one of the world’s leading journals in the whole field of paediatrics. DMCN disseminates a range of information worldwide to improve the lives of disabled children and their families. The high quality of published articles is maintained by expert review, including independent statistical assessment, before acceptance.